Park Sung-Shin, Kim Sung-Won
Department of Pathology, Dongguk University International Hospital, Dongguk, Korea.
Oncol Rep. 2007 Jul;18(1):139-43.
Akt/PKB is a serine/threonine kinase that plays a crucial role in cell survival and apoptosis. Aberrant activation of pAkt is associated with various malignant human cancers, including breast carcinoma. In vitro studies show that pAkt activation is mediated by estrogen and acts as a downstream effector of HER2 with implications in breast cancer progression and drug resistance. We investigated the incidence of Akt activation in invasive ductal carcinoma and its correlation with other clinicopathological variables. Using tissue microarray technology, immunohistochemical expression of phosphorylated Akt (pAkt) at Ser-473 was evaluated in 127 cases of invasive ductal carcinomas, together with hormone receptors, HER2, p53, Ki-67 and other clinicopathological variables. Both nuclear and cytoplasmic expression was noted for pAkt, with 46 cases (36.2%) showing high cytoplasmic pAkt expression and 37 cases (29.1%) showing high nuclear pAkt expression. There was a significant association between both high cytoplasmic and nuclear pAkt expression with HER2 overexpression (both p<0.0001). There was also a positive correlation between high nuclear pAkt expression with both estrogen receptor and progesterone receptor status (p=0.042 and p=0.015, respectively). High cytoplasmic pAkt expression was associated with high Ki-67 expression (p=0.052), however, there was no association between pAkt and p53 expression. In the present study, activation of the Akt pathway shows strong association with HER2 overexpression, which is consistent with many in vitro studies. Our study also showed a positive correlation between pAkt and hormone receptors, which suggested the possible mechanism of endocrine resistance in ER-positive breast cancer. These results also suggest the prognostic value of pAkt and its importance in the prediction of therapeutic response in invasive ductal carcinoma of the breast.
Akt/PKB是一种丝氨酸/苏氨酸激酶,在细胞存活和凋亡中起关键作用。pAkt的异常激活与多种人类恶性肿瘤相关,包括乳腺癌。体外研究表明,pAkt激活由雌激素介导,并作为HER2的下游效应因子,与乳腺癌进展和耐药性有关。我们研究了浸润性导管癌中Akt激活的发生率及其与其他临床病理变量的相关性。使用组织芯片技术,在127例浸润性导管癌中评估了Ser-473位点磷酸化Akt(pAkt)的免疫组化表达,同时检测了激素受体、HER2、p53、Ki-67和其他临床病理变量。pAkt在细胞核和细胞质中均有表达,46例(36.2%)显示高细胞质pAkt表达,37例(29.1%)显示高细胞核pAkt表达。高细胞质和高细胞核pAkt表达均与HER2过表达显著相关(均p<0.0001)。高细胞核pAkt表达与雌激素受体和孕激素受体状态也呈正相关(分别为p=0.042和p=0.015)。高细胞质pAkt表达与高Ki-67表达相关(p=0.052),然而,pAkt与p53表达之间无关联。在本研究中,Akt通路的激活与HER2过表达密切相关,这与许多体外研究一致。我们的研究还显示pAkt与激素受体呈正相关,这提示了雌激素受体阳性乳腺癌内分泌耐药的可能机制。这些结果也提示了pAkt的预后价值及其在预测乳腺浸润性导管癌治疗反应中的重要性。